This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Papavasiliou, A. S. Articles by Kotsalis, C. Search for Related Content PubMed PubMed Citation Articles by Papavasiliou, A. S. Articles by Kotsalis, C. Pubmed/NCBI databases Medline Plus Health Information Developmental Disabilities Social Bookmarking                         What's this?

Neurometabolic Testing in Developmental Delay

Department of Pediatric Neurology Pendeli Children's Hospital Athens, Greece, plotinus{at}otenet.gr

Helen Bazigou, MD

Department of Pediatric Neurology Pendeli Children's Hospital Athens, Greece

Evagelos Paraskevoulakos, MD

Department of Pediatric Neurology Pendeli Children's Hospital Athens, Greece

Charalambos Kotsalis, MD

Department of Pediatric Neurology Pendeli Children's Hospital Athens, Greece

The goal of this study was to examine the usefulness of neurometabolic testing in patients with unexplained developmental delay. We included 118 patients from ages 3 months to 13 years. The evaluation was conducted according to a protocol that called for stepwise investigations with the intention to minimize unnecessary tests. Clinical and neuroradiologic abnormalities were used as guidelines for the type and extent of the neurometabolic work-up. Based on our results, a diagnosis for a neurometabolic disorder was established in 16 patients (13.6%). Findings regarding abnormal metabolites (amino acids, ammonia, lactate, pyruvate, urine organic acids) did not lead to a diagnosis but to further investigations. Abnormalities in lysosomal enzymes, very-long-chain fatty acids, and urine mucopolysaccharides were definitive in establishing a diagnosis. In conclusion, in children with slowly progressing development with no apparent cause, there is a need for guidelines regarding the type of patients who need to be tested and the kind and extent of neurometabolic diagnostic work-up. (J Child Neurol 2000;15:620-622).

Journal of Child Neurology, Vol. 15, No. 9, 620-622 (2000)
DOI: 10.1177/088307380001500909


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L McDonald, A Rennie, J Tolmie, P Galloway, and R McWilliam Investigation of global developmental delay. Arch. Dis. Child., August 1, 2006; 91(8): 701 - 705. [Abstract] [Full Text] [PDF]

				J. B. Moeschler, M. Shevell, and and the Committee on Genetics Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics, June 1, 2006; 117(6): 2304 - 2316. [Abstract] [Full Text] [PDF]

				M. Shevell, S. Ashwal, D. Donley, J. Flint, M. Gingold, D. Hirtz, A. Majnemer, M. Noetzel, and R.D. Sheth Practice parameter: Evaluation of the child with global developmental delay: Report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society Neurology, February 11, 2003; 60(3): 367 - 380. [Abstract] [Full Text] [PDF]